Morgan Stanley analyst David Lewis increased his price target on Intuitive Surgical to $575 from $535, stating that "inflection in the core is evident" given the better than expected procedure growth and system upside reported in Q2. With trends in procedures and systems strong, he is confident in growth sustainability and he is additionally confident that Intuitive will not only to maintain technological leadership but materially expand its addressable market with new introductions, Lewis tells investors. He maintains an Overweight rating on Intuitive shares.